- Algernon Pharmaceuticals (OTCQB:AGNPF) announces that it has now enrolled 75% of its enrollment target, which is 113 patients, for its multinational Phase 2b/3 human study of NP-120 (Ifenprodil) for the treatment of COVID-19.
- The trial will be conducted in the U.S., Australia, the Philippines and Romania.
- Company projects completion of study in November 2020 with a planned data readout before Q4 end.
- Press Release
- https://seekingalpha.com/news/3619387-algernon-pharmaceuticals-progress-on-human-study-for-covid-drug
Friday, October 2, 2020
Algernon Pharma progress on human study for Covid drug
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.